[1] Yang CM, Shu J. Cholangiocarcinoma evaluation via imaging and artificial intelligence. Oncology, 2021, 99(2):72-83. [2] Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res, 2021, 149(4):321-387. [3] Kovač JD, Janković A, Dikić-Rom A, et al. Imaging spectrum of intrahepatic mass-forming cholangiocarcinoma and its mimickers: how to differentiate them using MRI. Curr Oncol, 2022, 29(2):698-723. [4] Tawarungruang C, Khuntikeo N, Chamadol N, et al. Survival after surgery among patients with cholangiocarcinoma in northeast Thailand according to anatomical and morphological classification. BMC Cancer, 2021, 21(1):497-508. [5] Zhou Y, Yin S, Zhao L, et al. CEUS and CT/MRI LI-RADS in association with serum biomarkers for differentiation of combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma. Front Oncol, 2022, 12(3):897-906. [6] Kim YY, Yeom SK, Shin H, et al. Clinical staging of mass-forming intrahepatic cholangiocarcinoma: computed tomography versus magnetic resonance imaging. Hepatol Commun, 2021, 5(12):2009-2018. [7] Zhao F, Pang G, Li X, et al. Value of perfusion parameters histogram analysis of triphasic CT in differentiating intrahepatic mass forming cholangiocarcinoma from hepatocellular carcinoma. Sci Rep, 2021, 11(1):163-172. [8] 陈淑宽,宋振强,张龙. 常规MRI序列、MRCP序列及DWI序列在术前诊断良恶性壶腹周围病变中的应用. 中国CT和MRI杂志,2020,18(6):104-106,152. [9] 蔡秀军,陈鸣宇,曹佳胜. 美国国家综合癌症网络肝胆肿瘤临床实践指南2020年版更新解读(CC部分). 临床外科杂志,2021,29(1):7-10. [10] Kim NH, Lee SR, Kim YH, et al. Diagnostic performance and prognostic relevance of FDG positron emission tomography/computed tomography for patients with extrahepatic cholangiocarcinoma. KoreanJ Radiol, 2020, 21(12):1355-1366. [11] Zhou N, Hu A, Shi Z, et al. Inter-observer agreement of computed tomography and magnetic resonance imaging on gross tumor volume delineation of intrahepatic cholangiocarcinoma: an initial study. Quant Imaging Med Surg, 2021, 11(2):579-585. [12] Zhou J, Zhang Y, Chang KT, et al. Diagnosis of benign and malignant breast lesions on DCE-MRI by using radiomics and deep learning with consideration of peritumor tissue. J Magn Reson Imaging, 2020, 51(3):798-809. [13] Vandecaveye V, Dresen RC, Pauwels E, et al. Early whole-body diffusion-weighted MRI helps predict long-term outcome following peptide receptor radionuclide therapy for metastatic neuroendocrine tumors. Radiol Imaging Cancer, 2022, 4(3):95-104. [14] Ra iu I, Lupu oru R, Lungeanu D, et al. Diagnosis of malignant biliary obstruction: pondering over the ERCP, MRCP and histology. J Int Med Res, 2022, 50(2):924-935. [15] Xiang X, Liu Z, Zhang C, et al. IDH mutation subgroup status associates with intratumor heterogeneityand the tumor microenvironment in intrahepatic cholangiocarcinoma. Adv Sci (Weinh), 2021, 8(17):230-238. [16] De Vuysere S, Vandecaveye V, De Bruecker Y, et al. Accuracy of whole-body diffusion-weighted MRI (WB-DWI/MRI) in diagnosis, staging and follow-up of gastric cancer, in comparison to CT: a pilot study. BMC Med Imaging, 2021, 21(1):18-25. [17] Connor S, Sit C, Anjari M, et al. The ability of post-chemoradiotherapy DWI ADCmean and18F-FDG SUVmax to predict treatment outcomes in head and neck cancer: impact of human papilloma virus oropharyngeal cancer status. J Cancer Res Clin Oncol, 2021, 147(8):2323-2336. [18] Song J, Gu Y, Du T, et al. Analysis of quantitative and semi-quantitative parameters of DCE-MRI in differential diagnosis of benign and malignant cervical tumors. Am J Transl Res, 2021, 13(11):12228-12234. [19] Wang GX, Ge XD, Zhang D, et al. MRCP combined with CT promotes the differentiation of benign and malignant distal bile duct strictures. Front Oncol, 2021, 11(2):683-689. [20] Goldfinger MH, Ridgway GR, Ferreira C, et al. Quantitative MRCP imaging: accuracy, repeatability, reproducibility, and cohort-derived normative ranges. J Magn Reson Imaging, 2020, 52(3):807-820. |